UCL to Trial Dimethyltryptamine (DMT) on UK Volunteers to Combat Alcohol Misuse
Jan 19, 2025, 12:45 PM
Scientists at University College London (UCL) are set to trial the psychedelic drug dimethyltryptamine (DMT) on UK volunteers in an effort to address alcohol misuse. The study aims to determine whether a single dose of this powerful hallucinogen can assist individuals in reducing their alcohol intake. DMT, known for its use in traditional healing ceremonies, has garnered interest as a potential therapeutic agent in treating substance dependence. This initiative aligns with broader discussions in the European Union regarding the regulation and funding of psychedelic therapies, as various organizations advocate for equitable access to such treatments across member states.
View original story
Markets
Yes • 50%
No • 50%
Official regulatory announcements from EU member countries
Yes • 50%
No • 50%
Official announcements from the European Union
Yes • 50%
No • 50%
Results published by University College London or in a peer-reviewed journal
Germany • 25%
Spain • 25%
Other • 25%
France • 25%
Official announcements from EU member states or research institutions
Netherlands • 25%
Other • 25%
Germany • 25%
Portugal • 25%
Official regulatory announcements from EU member countries
Increase in alcohol intake • 25%
Significant reduction in alcohol intake • 25%
Moderate reduction in alcohol intake • 25%
No significant change in alcohol intake • 25%
Results published by University College London or in a peer-reviewed journal